Please assess the completion status of the following clinical trial:

Trial Title: Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Subject aged between 18 and 57 years (i.e., less than 60 at the last vaccination)~* For woman of child-bearing potential, negative urine pregnancy test at V#01~* Use of effective contraception prior to and during the trial~* Subject available during the trial period~* Subject able to read and understand the informed consent form~* Informed consent form signed and dated by the subject prior to any protocol-required intervention (and Visit 05 and Visit 07, respectively).~Exclusion Criteria :~* Self-reported allergy to egg proteins, chick proteins, or any of the constituents of the vaccine, in particular, neomycin, formaldehyde, and octoxinol 9~* Acute febrile disease within the 72 hours preceding V#01, or axillary temperature \>37.5°C the day of inclusion, prior to vaccination (\>37.0°C Czech Republic)~* Subject with an aggravation of existing chronic illness (heart disease, respiratory disease, etc.)~* Vaccination against influenza within the 6 months preceding V#01~* Any vaccination within the 28 days preceding V#01 or scheduled between V#01 and V#02~* Breast-feeding~* Immunosuppressive therapy including long term systemic corticotherapy (20 mg/day of prednisolone or equivalent for \>2 weeks) or cancer therapy within the month preceding V#01 or ongoing~* Immunoglobulin injection within the 3 months preceding V#01~* Subject taking part or planned to take part in another clinical trial (3 months before and through the trial duration)~* Subject having received extracted pituitary hormones~* Subjects who participated in the GID01 study (Lithuanian centers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 57 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).